Starsource Multitrade

Starsource Multitrade Margine EBITDA

Il Margine EBITDA di Starsource Multitrade (506365.BO) al 19 ott 2026 è -1,03 %. L'anno precedente, Margine EBITDA era 65,46 % — una variazione del -101,57% (inferiore).

Margine EBITDA

-1,03 %

YoY

-101,57%

Ultimo aggiornamento:

Margine EBITDA di Starsource Multitrade ammonta a 2026 -1,03 % . Margine EBITDA di Starsource Multitrade ammontava a 2025 65,46 % . Diminuisce del -101,57% inferiore rispetto all'anno precedente.

La storia di Starsource Multitrade Margine EBITDA

  • 3 anni

  • 10 anni

  • 25 anni

  • Max

Margine EBITDA
Data
Margine EBITDA
1 gen 2014
71,40 INR
1 gen 2015
80,32 INR
1 gen 2016
65,46 INR
1 gen 2026
-1,03 INR
La storia di Starsource Multitrade Margine EBITDA
ANNOMargine EBITDAYoY
-1,03 %-101,57%
65,46 %-18,49%
80,32 %+12,50%
71,40 %—

Accedi a questi dati tramite l’API Eulerpool

100.000 richieste/mese gratis · nessuna carta di credito

Starsource Multitrade Analisi delle Azioni

Cosa fa Starsource Multitrade? Starsource Multitrade Ltd, identified by the ticker symbol 506365.BO and ISIN INE320M01019, is a corporate entity registered in India with its headquarters located in Mumbai, Maharashtra. The company was originally established through an initial public offering on January 2, 1995. While the specific sector and industry classifications are currently listed as not applicable, the company's operational history and strategic direction are closely tied to its former identity as Chemo Pharma Laboratories Ltd. This previous incarnation operated within the pharmaceutical industry, focusing on the development and distribution of healthcare products. However, the corporate landscape has shifted significantly, and the entity is no longer engaged in its original pharmaceutical activities. According to available information, the firm currently has no active operations within its traditional business lines. Instead, the organization is in a transitional phase, actively exploring new business opportunities to redefine its market presence. The strategic intent of the current management is to pivot away from pharmaceuticals and acquire businesses in the power and chemicals sectors. This move represents a substantial change in the company's core focus, aiming to diversify its portfolio and enter entirely different industrial segments. The company's official website, https://www.thechemopharmalaboratoriesltd.com/, reflects its historical branding, although the operational reality has evolved. Investors and stakeholders monitoring the company should note that the absence of current operations means that recent financial performance may not reflect traditional revenue streams associated with pharmaceutical manufacturing or sales. The focus is currently on strategic acquisitions and business development rather than organic growth from existing products. The transition from a pharmaceutical manufacturer to a holding or investment vehicle targeting power and chemical assets suggests a long-term restructuring plan. Until new acquisitions are finalized and integrated, the company remains in a state of exploration and preparation. The headquarters in Mumbai serves as the administrative center for these strategic discussions and future operational planning. The lack of a defined sector classification further underscores the company's current status as an entity in flux, waiting for new business units to be acquired and operationalized. This profile highlights the significant shift from its historical roots in healthcare to its current ambitions in energy and industrial chemicals, marking a distinct chapter in the company's corporate evolution. Starsource Multitrade è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Starsource Multitrade azioni

Margine EBITDA di Starsource Multitrade è -1,03 % nel 2026.

Il Margine EBITDA di Starsource Multitrade è passato da 65,46 % a -1,03 %, con una variazione del -101,57 %. Il valore è inferiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Starsource Multitrade di Margine EBITDA dal 2006, con valori annuali, grafici e analisi dettagliate.

Il margine EBITDA mostra quale percentuale dei ricavi si converte in EBITDA. Normalizza le differenze di ammortamento e struttura del capitale.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Starsource Multitrade di Margine EBITDA con i competitor del settore e la media industriale per valutare se è attraente.

Per valutare di Margine EBITDA, è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per Margine EBITDA.

Accedi a questi dati tramite l’API Eulerpool

100.000 richieste/mese gratis · nessuna carta di credito

Margini — Starsource Multitrade

Tutte le Metriche Finanziarie — Starsource Multitrade